HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miyazaki, Y. Articles by DeFronzo, R. A. Search for Related Content PubMed PubMed Citation Articles by Miyazaki, Y. Articles by DeFronzo, R. A. Social Bookmarking                What's this?

Dose-Response Effect of Pioglitazone on Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes

University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas

	ABSTRACT

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 
OBJECTIVE—To investigate the dose-response effects of pioglitazone on glycemic control, insulin sensitivity, and insulin secretion in patients with type 2 diabetes.

RESEARCH DESIGN AND METHODS—A total of 58 diet-treated patients with type 2 diabetes (aged 54 ±1 years; 34 men and 24 women; BMI 31.5± 0.6 kg/m²) were randomly assigned to receive placebo (n=11) or 7.5 mg (n=13), 15 mg (n=12), 30 mg (n=11), or 45 mg (n=11) of pioglitazone per day for 26 weeks. Before and after 26 weeks, subjects underwent a 75-g oral glucose tolerance test (OGTT).

RESULTS—Patients treated with 7.5 or 15 mg/day of pioglitazone had no change in fasting plasma glucose (FPG) and fasting plasma insulin (FPI) concentrations or in plasma glucose (PG) and insulin concentrations during the OGTT. Patients treated with 30 and 45 mg/day of pioglitazone, respectively, had significant decreases from placebo in HbA_1c (=-2.0 and -2.9%), FPG (=-66 and -97 mg/dl), and mean PG during OGTT (=-84 and -107 mg/dl). Fasting plasma insulin decreased significantly in the 45-mg/day pioglitazone group, but the mean plasma insulin during the OGTT did not change. The insulinogenic index ( area under the curve [AUC] insulin/AUC glucose) during the OGTT increased significantly in the 30- and 45-mg/day pioglitazone groups (0.13± 0.03 to 0.27± 0.05, P < 0.05). From the OGTT, we previously have derived a composite whole-body insulin sensitivity index (ISI) that correlates well with that measured directly with the insulin clamp technique. Whole-body ISI [ISI=10,000 , where and equal mean plasma glucose and insulin concentrations during OGTT] increased significantly in patients treated with 30 mg (1.8± 0.3 to 2.5± 0.3, P < 0.05) or 45 mg (1.6± 0.2 to 2.7± 0.6, P < 0.05) per day of pioglitazone. In the basal state, the hepatic ISI [k/(FPG x FPI)[k/(FPG x FPI)], which agrees closely with that measured directly with tritiated glucose, increased in patients treated with 30 mg (0.13± 0.02 to 0.21± 0.03, P < 0.05) and 45 mg (0.11± 0.02 to 0.24± 0.06, P < 0.05) per day of pioglitazone. Significant correlations between the dose of pioglitazone and the changes in HbA_1c (r=-0.58), FPG (r=-0.47), mean PG during the OGTT (r=-0.46), insulinogenic index (r=0.34), hepatic ISI (r=0.44), and whole-body ISI (r=0.36) were observed.

CONCLUSIONS—Pioglitazone improves glycemic control through the dose-dependent enhancement of ß-cell function and improved whole-body and hepatic insulin sensitivity.

Abbreviations: AUC, area under the curve • FPG, fasting plasma glucose • FPI, fasting plasma insulin • ISI, insulin sensitivity index • OGTT, oral glucose tolerance test • PG, plasma glucose • PPAR, peroxisome proliferator–activated receptor-

	INTRODUCTION

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 
Thiazolidinediones, a new class of insulin-sensitizing agents, recently have been introduced for the treatment of patients with type 2 diabetes. Early studies showed that troglitazone ameliorates insulin resistance and improves hyperglycemia and hyperinsulinemia in type 2 diabetes (1,2). Thiazolidinediones activate a specific nuclear receptor, termed peroxisome proliferator–activated receptor- (PPAR) (3), causing preadipocytes to differentiate into mature fat cells and inducing key lipogenic enzymes (3,4). A close relationship exists between the ability of various thiazolidinediones to activate PPAR and their hypoglycemic action (5). Pioglitazone, a relatively new member of the thiazolidinedione class, improves hyperglycemia, reduces hyperinsulinemia, and ameliorates hypertriglyceridemia in a variety of insulin-resistant animal models of impaired glucose tolerance (6). Recently, Aronoff et al. (7) demonstrated a dose-dependent beneficial effect of pioglitazone monotherapy on glycemic control in type 2 diabetic patients in a large-scale multicenter trial. However, only one previous study has examined the effect of pioglitazone on insulin sensitivity in diabetic humans (8), and no clinical study has examined the dose-dependent effect of pioglitazone on insulin sensitivity in vivo. Previously, we derived a composite index of whole-body insulin sensitivity during 75-g oral glucose tolerance testing (OGTT) and demonstrated that this index correlates well with that measured directly with the insulin clamp technique (9). Using this insulin sensitivity index (ISI), we have examined the dose-dependent effect of pioglitazone on whole-body insulin sensitivity and insulin secretion in 58 patients with type 2 diabetes after 26 weeks of treatment with pioglitazone or placebo. This analysis provides important new information about the mechanism, as well as the dose-response characteristics of pioglitazone, in the treatment of patients with type 2 diabetes.

	RESEARCH DESIGN AND METHODS

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 
Study design
A total of 58 patients with type 2 diabetes underwent 75-g OGTT before and after 26 weeks of pioglitazone therapy in a randomized, double-blind, placebo-control, multicenter clinical trial. To be eligible, patients were required to have HbA_1c 7.0%, fasting plasma glucose (FPG) 140 mg/dl, and fasting C-peptide >1 ng/ml. Patients who used insulin or who had unstable proliferative retinopathy, impaired liver function (aspartate aminotransferase or alanine aminotransferase >2.5 x upper limit of normal), impaired kidney function (serum creatinine >1.8 mg/dl), or anemia were excluded. Patients taking previous antidiabetic therapy (sulfonylureas or metformin) underwent a 6- to 8-week single-blind washout period before the baseline OGTT was performed. After the washout period, only patients with HbA_1c 7.0% were enrolled. Patients were randomized to one of five parallel treatment groups: pioglitazone 7.5, 15, 30, or 45 mg/day or placebo. During the double-blind period, patients were seen every 2 weeks for the first 6 weeks and every 4 weeks for the remaining 20 weeks. At 26 weeks, all subjects underwent repeat 75-g OGTT. To minimize the confounding effect of weight loss on metabolic changes, no specific dietary modifications were recommended during the study.

Measurements
During the OGTT, plasma glucose (PG) concentration was measured at 0, 1, and 2 h by the hexokinase method (Hitachi 747-200 Analyzer; Roche, Indianapolis, IN). Plasma insulin concentration was measured at 0, 1, and 2 h during OGTT by an automated enzyme immunoassay (Tosoh AIA-1200; Tosoh Medicus, South San Francisco, CA). HbA_1c was measured by automated ion-exchange high-performance liquid chromatography (Bio-Rad Variant Analyzer; Bio-Rad Diagnostics, Hercules, CA). Fasting serum lipid levels (total cholesterol, HDL cholesterol, and triglycerides) were determined enzymatically (Hitachi 747 Analyzer; Roche, Indianapolis, IN). LDL cholesterol was calculated from the Friedewald equation.

Calculations
The whole-body ISI was determined from the OGTT as follows (9):

where FPI=fasting plasma insulin (µU/ml), FPG=fasting plasma glucose (mg/dl), and and represent the mean plasma glucose and plasma insulin concentrations during OGTT. This index provides a composite measure of the combined effects of hyperinsulinemia plus hyperglycemia on muscle and hepatic glucose metabolism and is highly correlated with insulin sensitivity measured with the euglycemic insulin clamp technique (9). In the previous study (9), whole-body ISI was calculated from PG and insulin concentrations measured every 30 min during OGTT. In the present study, PG and insulin were measured every hour during the OGTT. Therefore, using the previously published data (9), we reanalyzed the relationship between insulin sensitivity obtained from euglycemic insulin clamp and ISI derived from PG and insulin concentrations at 0, 1, and 2 h during OGTT. A highly significant correlation between these parameters was observed in nondiabetic (r=0.74, P < 0.001) and type 2 diabetic (r=0.67, P < 0.001) individuals.

Hepatic insulin sensitivity can be estimated from the FPG and FPI as follows (9,10):

This equation is mathematically equivalent to the reduced formula of the homeostasis model assessment (HOMA) (10), where k=22.5 x 18, and the index of hepatic insulin sensitivity correlates closely with that measured directly with tritiated glucose (9).

Statistical analysis
Statistical calculations were performed using StatView for Windows software (version 5.0; SAS Institute, Cary, NC). Values before and after treatment within each group were analyzed using paired Student’s t test. Comparison between groups was performed using ANOVA with Bonferroni/Dunn post-hoc testing. Comparisons over time were made using repeated measures ANOVA. Pearson’s correlations between continuous variables were used as a measure of association. For the association between the five groups and changes in metabolic variables after treatment with pioglitazone or placebo, we also reevaluated the significance using Spearman’s correlation coefficient by rank. All data are presented as the mean± SEM. P < 0.05 was considered statistically significant.

	RESULTS

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 
Patient characteristics, HbA_1c, glucose, insulin, and lipids
Fifty-eight patients were randomized to receive placebo (n=11) or 7.5 (n=13), 15 (n=12), 30 (n=11), or 45 (n=11) mg/day of pioglitazone. At baseline, there were no significant differences in age, ethnicity, sex, BMI, HbA_1c, FPG, or insulin concentrations between the placebo and four pioglitazone-treated groups (Table 1). There tended to be more men than women in the pioglitazone-treated groups compared with the placebo group. Within the four pioglitazone-treated groups, the distribution of men and women was similar. It is known that men respond less well to thiazolidinediones than women because of their lower percentage of body fat (11). Plasma lipid levels were similar in the pioglitazone and placebo groups (Table 1).

OGTT
During the baseline study, there were no statistically significant differences in FPG or FPI concentrations, the incremental area under the plasma glucose curve (AUC glucose) and the incremental area under the plasma insulin curve (AUC insulin) during the OGTT, the insulinogenic index (AUC insulin/AUC glucose) from 0 to 120 min, the hepatic insulin sensitivity index, or the whole-body ISI between the placebo and each pioglitazone group (Table 2). After 26 weeks of treatment with 30 and 45 mg/day of pioglitazone, the PG concentration during OGTT was significantly reduced from baseline (P < 0.01–0.05) and from placebo (P < 0.01–0.05) (Table 2). In both the 30- and 45-mg/day pioglitazone groups, the AUC glucose was also significantly reduced compared with the pretreatment OGTT (Table 2). After 26 weeks, the incremental plasma insulin responses during the OGTT were similar in the placebo, 7.5-mg pioglitazone, and 15-mg/day pioglitazone groups. However, the AUC insulin increased significantly in the 30-mg/day pioglitazone group (P=0.03 versus placebo) and the 45-mg/day pioglitazone group (P < 0.01 versus placebo and versus baseline). After 26 weeks of pioglitazone treatment, the insulinogenic index (AUC insulin/AUC glucose from 0 to 120 min) increased significantly in the 30-mg/day pioglitazone group (P < 0.05 versus baseline and P=0.07 versus placebo) and the 45-mg/day pioglitazone group (P 0.02 versus placebo and baseline) (Table 2). The hepatic ISI increased significantly versus placebo in the 15-, 30-, and 45-mg/day pioglitazone treatment groups (Table 2). The whole-body ISI increased in the 30- and 45-mg/day pioglitazone treatment groups compared with baseline and placebo (Table 2).

View larger version (34K): [in this window] [in a new window]   Figure 1— Dose-response relation between pioglitazone and the changes in body weight (BW), HbA1c, FPG, mean PG during the OGTT, the incremental insulin area during the OGTT (AUC insulin), insulinogenic index from 0 to 120 min [IGI (120 min)], hepatic ISI, and whole-body ISI in patients with type 2 diabetes. The Pearson’s correlation coefficient and associated P value are shown. The Spearman’s correlation coefficient is shown in parentheses.

	CONCLUSIONS

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

The AUC glucose during OGTT decreased significantly from baseline in the 30- and 45-mg/day pioglitazone groups (Table 1). This beneficial effect of pioglitazone on postprandial hyperglycemia is quite distinct from sulfonylureas (12) and metformin (13), which exert their primary effect on the FPG concentration. Although the meglitinides reduce the postprandial glucose excursion, their effect on FPG is quite modest (14). The improvement in postprandial hyperglycemia after pioglitazone treatment could result from 1) increased insulin secretion, 2) enhanced tissue (peripheral and/or hepatic) sensitivity to insulin, or 3) an improvement in the combined effects of hyperglycemia plus hyperinsulinemia to promote glucose metabolism.

The effect of thiazolidinedione treatment on insulin secretion in patients with type 2 diabetes is controversial (1,11,15,16). Some studies have reported a decrease in plasma insulin response to a glucose challenge (1,11), whereas others have failed to observe any significant change (15,16). We found an increase in plasma insulin response during OGTT in diabetic patients treated with 30 and 45 mg/day of pioglitazone (Table 2). An increased or maintained plasma insulin response in the presence of a decreased PG concentration suggests an improvement in ß-cell function. Consistent with this, pioglitazone (30- and 45-mg/day dose) increased the insulinogenic index (AUC insulin/AUC glucose) (Table 2). We believe that the variable effect of thiazolidinediones on the plasma insulin response to a glucose challenge is explained by two opposing effects: 1) a decrease in fasting and postprandial glucose concentrations, leading to reduced glucose toxicity (17); and 2) an increase in insulin sensitivity, leading to reduced insulin secretion (18).

Previous studies with thiazolidinediones in patients with type 2 diabetes concluded that their primary mechanism of action is related to improved insulin sensitivity (1,16,19,20). However, each of these insulin clamp studies used pharmacologic insulin infusion rates (80,120, or 300 mU · m ^–2 ·min ^–1), which produced supraphysiologic plasma insulin concentrations. In a recent study (8) using more physiologic plasma insulin concentrations, pioglitazone had only a very modest effect to enhance insulin sensitivity in patients with type 2 diabetes. In the present study, 26 weeks of pioglitazone treatment (30 and 45 mg/day) significantly increased the whole-body ISI compared with baseline and compared with placebo (Table 2). This improvement in whole-body ISI was observed with mean plasma insulin concentrations of 36–46 µU/ml (Table 2). It is important to note that there are significant differences between the OGTT and euglycemic insulin clamp, including the presence (OGTT) or absence (euglycemic insulin clamp) of hyperglycemia and the route of glucose administration (oral versus intravenous). Moreover, in contrast to the insulin clamp, the whole-body ISI during OGTT is greatly influenced by 1) glucose-mediated glucose uptake and the combined effects of hyperinsulinemia plus hyperglycemia to augment glucose disposal, 2) less effective suppression of hepatic glucose production (21), and 3) splanchnic uptake of 30–40% of the ingested glucose load (21). With regard to the latter, Kawamori et al. (22) have suggested that pioglitazone augments splanchnic glucose uptake after glucose ingestion. These considerations suggest that mechanisms, in addition to improved insulin sensitivity in muscle, contribute to the improvement in whole-body insulin sensitivity during OGTT after pioglitazone therapy.

From the dose-response standpoint, the insulin-sensitizing effect of pioglitazone is clearly evident at doses of 30 and 45 mg/day (Table 2). There was a tendency for whole-body insulin sensitivity to increase at 15 mg/day, but this did not reach statistical significance. Although whole-body insulin sensitivity and dose of pioglitazone were linearly related (Fig. 1), the threshold for a clinically significant insulin-sensitizing effect on glucose homeostasis is 15 mg/day of pioglitazone.

The product of basal hepatic glucose production (measured with tritiated glucose) and the FPI concentration provides a direct measure of hepatic insulin resistance under postabsorptive conditions, whereas the inverse provides a measure of hepatic insulin sensitivity (9). Because basal hepatic glucose production is closely correlated with FPG concentration (23), the inverse of the product of FPG and insulin concentrations provides an index of hepatic insulin sensitivity (9). The hepatic ISI increased in the 15-, 30-, and 45-mg/day pioglitazone groups (P < 0.05–0.01 versus placebo). Previous studies examining the effect of troglitazone on basal hepatic glucose production provided apparently contradictory results (1,16,20). In two studies, troglitazone reduced hepatic glucose production (1,20), whereas one study (16) found no effect of troglitazone on basal glucose output by the liver. However, these studies failed to relate the basal rate of hepatic glucose production to the fasting plasma insulin concentration. Because troglitazone treatment was associated with a decrease in FPI, a decreased or even unchanged rate of hepatic glucose production implies an improvement in hepatic insulin sensitivity.

In type 2 diabetic subjects, weight gain causes worsening of insulin resistance and deterioration of glycemic control. In the present study, pioglitazone treatment (15–45 mg/day) for 26 weeks was associated with mean weight gain of 2.0–4.5 kg, which was significantly and inversely correlated with decreases in HbA_1c (r=-0.527, P < 0.0001), FPG (r=-0.381, P=0.03), and mean PG concentration during OGTT (r=-0.462, P < 0.001). Improved glycemic control, despite weight gain, has been reported with other thiazolidinediones, including rosiglitazone and troglitazone (11,15). Although decreased glucosuria (associated with improved glycemic control) could contribute to the weight gain, this would not be expected to enhance insulin sensitivity. The seemingly paradoxical relationship between weight gain and improved glucose homeostasis/insulin sensitivity most likely is explained by the basic cellular mechanism of action of the thiazolidinediones, which exert their effects through the PPAR (3,4). PPAR receptors are found primarily in adipose tissue (3), and their activation causes preadipocytes to differentiate into mature small fat cells (3,4). PPAR activation also induces key enzymes involved in lipogenesis in these newly formed adipocytes (3,4). Plasma free fatty acids provide the major source of lipid for triglyceride synthesis in these newly formed adipocytes (3). Although PPAR receptors are present in both visceral and subcutaneous adipose tissue in humans, thiazolidinediones cause the differentiation of preadipocytes into mature adipocytes only in subcutaneous fat depots (24). This most likely explains the finding that thiazolidinedione-induced weight gain is associated with an increase in subcutaneous fat tissue and a decrease in visceral abdominal fat content (15,25). Because increased visceral fat is associated with insulin resistance (26), a reduction in visceral fat would be expected to lead to an enhancement in insulin sensitivity. Moreover, elevated plasma free fatty acid concentrations/oxidation are common in type 2 diabetic patients and cause insulin resistance in both liver and muscle (27,28). Because thiazolidinedione treatment consistently reduces plasma free fatty acid levels (11,20,29), this may provide another explanation for the improvement in insulin sensitivity despite weight gain.

Dose-response analyses demonstrated significant linear, positive associations between the pioglitazone dose and decrements in HbA_1c, FPG, and mean PG concentration during OGTT, as well as between pioglitazone dose and increases in body weight, AUC insulin, insulinogenic index, and hepatic and whole-body ISI (Fig. 1). These significant associations were observed whether or not the placebo group was included in the analysis. Although we cannot determine the maximally effective dose of pioglitazone from the present study, it can be concluded that pioglitazone (at doses ranging from 15 to 45 mg/day) causes a dose-dependent decrease in fasting and postprandial PG concentrations through improvements in hepatic/whole-body insulin sensitivity and in ß-cell function in type 2 diabetic patients. For most metabolic parameters, statistically significant changes from baseline and from placebo are evident with pioglitazone doses of 30 and 45 mg/day, with a tendency for the changes to become significant at 15 mg/day. Although some type 2 diabetic patients may respond to a pioglitazone dose of 15 mg/day when given as monotherapy, most will require 30 mg/day to see clinically significant effects on insulin sensitivity, enhanced ß-cell function, and improved glucose homeostasis.

	Acknowledgments

 
Support for the multicenter trial was provided by Takeda.

We thank Elva Chapa and Lorrie Albarado for expert secretarial assistance in preparing the manuscript.

	Footnotes

 
Address correspondence and reprint requests to Ralph A. DeFronzo, MD, University of Texas Health Science Center, Diabetes Division, Room #3.380S, 7703 Floyd Curl Dr., San Antonio, TX 78229-3900.

Received for publication 18 June 2001 and accepted in revised form 6 November 2001.

R.A.D. has received a research grant from and is on the advisory board and the National Speakers Bureau of Takeda Pharmaceuticals.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

	References

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 

1. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI: Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus; a randomized, double-blind, placebo-controlled trial. Ann Intern Med 128:176–185, 1998[Abstract/Free Full Text]
   
2. Fonseca VA, Valiquett TR, Huang SM, Ghazzi MN, Whitcomb RW, and the Troglitazone Study Group: Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. J Clin Endocrinol Metab 83:3169–3176, 1998[Abstract/Free Full Text]
   
3. Spiegelman BM: PPAR-: adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507–514, 1998[Abstract]
   
4. Hallakau S, Doare F, Foufelle F, Kergost M, Guerre-Millo, Berthault MF, Dugail I, Mortin J, Auwerx J, Farre P: Pioglitazone induces in vivo adipocyte differentiation in obese Zucker fa/fa rats. Diabetes 46:1393–1399, 1997[Abstract]
   
5. Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS, Saperstein R, Smith RG, Leibowitz MD: Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 137:4189– 4195, 1996[Abstract]
   
6. Kemnitz JW, Elson DF, Roecker EB, Baum ST, Bergman RN, Meglasson MD: Pioglitazone increase insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure in obese, insulin-resistant rhesus monkeys. Diabetes 43:204–211, 1994[Abstract]
   
7. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathsen A, Schneider R, The Pioglitazone 001 Study Group: Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care 23:1605–1611, 2000[Abstract/Free Full Text]
   
8. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahanlai S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA: Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24:710–719, 2001[Abstract/Free Full Text]
   
9. Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462–1470, 1999[Abstract/Free Full Text]
   
10. Turner R, Holman R, Matthews D, Hockaday T, Peto J: Insulin deficiency and insulin resistance interaction in diabetes: estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations. Metabolism 28:1086–1096, 1979[Medline]
    
11. Patel J, Anderson RJ, Rappaport EB: Rosiglitazone monotherapy improve glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes, Obesity and Metabolism 1:165–172, 1999[Medline]
    
12. Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT, The Glipizide Gastrointestinal Therapeutic System Study Group: Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Diabetes Care 20:597–606, 1997[Abstract]
    
13. DeFronzo RA, Goodman AM, and The Multicenter Metformin Study Group: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333:541–549, 1995[Abstract/Free Full Text]
    
14. Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S: Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 23:1660–1665, 2000[Abstract/Free Full Text]
    
15. Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Yajima N, Ikeda Y: Effects of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 22:908–912, 1999[Abstract]
    
16. Inzucchi SE, Maggs D, Spollet GR, Page SL, Rife FS, Walton V, Shulman GI: Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338:867–872, 1998[Abstract/Free Full Text]
    
17. Rossetti L, Giacarri A, DeFronzo RA: Glucose toxicity. Diabetes Care 13:610–630, 1990[Abstract]
    
18. Diamond MP, Thornton K, Connoly-Diamond M, Sherwin RS, DeFronzo RA: Reciprocal variation in insulin-mediated glucose uptake and pancreatic insulin secretion in women with normal glucose tolerance. J Soc Gynecol Invest 2:708–715, 1995
    
19. Frias JP, Yu JG, Kruszynska YT, Olefsky JM: Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects. Diabetes Care 23:64–69, 2000[Abstract]
    
20. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193–203, 1992[Abstract]
    
21. Ferrannini E, Reichard GA, Bjorkman O, Wahren J, Pilo A, Olsson M, DeFronzo RA: The disposal of an oral glucose load in healthy subjects: a quantitative study. Diabetes 34:580–588, 1985[Abstract]
    
22. Kawamori R, Matsuhisa M, Kinoshita J: Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 41:35– 43, 1998[Medline]
    
23. DeFronzo RA, Ferrannini E, Simpson DC: Fasting hyperglycemia in non-insulin dependent diabetes mellitus: contribution of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 38:387–395, 1989[Medline]
    
24. Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders L, Digby JE, Sewter CP, Lazer MA, Chatterjee VKK, O’Rahilly S: Activators of peroxisome proliferator-activated receptor have depot-specific effects on human preadipocyte differentiation. J Clin Invest 100:3149–3153, 1997[Medline]
    
25. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Cusi K, Mandarino L, DeFronzo RA: Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in patients with type 2 diabetes mellitus (Abstract). Diabetes 49 (Suppl. 1):A229, 2000
    
26. Evans DI, Hoffmann RG, Kalkhoff RK, Kissebah AH: Relationship of body fat topography to insulin sensitivity and metabolic profiles in premenopausal women. Metabolism 33:68–76, 1984[Medline]
    
27. Randle PJ, Garland PB, Hales CN, Newsholme EA: The glucose–fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1:785–789, 1963[Medline]
    
28. Boden G: Role of the fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3–10, 1997[Abstract]
    
29. Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardham R, Freed MI: Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 43:278– 284, 2000[Medline]
    

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				M. Massi-Benedetti and M. Orsini-Federici Treatment of Type 2 Diabetes With Combined Therapy: What are the pros and cons? Diabetes Care, February 1, 2008; 31(Supplement_2): S131 - S135. [Abstract] [Full Text] [PDF]

				A. McDonald, R. M Williams, F. M Regan, R. K Semple, and D. B Dunger IGF-I treatment of insulin resistance Eur. J. Endocrinol., August 1, 2007; 157(suppl_1): S51 - S56. [Abstract] [Full Text] [PDF]

				B. L. Wajchenberg {beta}-Cell Failure in Diabetes and Preservation by Clinical Treatment Endocr. Rev., April 1, 2007; 28(2): 187 - 218. [Abstract] [Full Text] [PDF]

				A. Gastaldelli, E. Ferrannini, Y. Miyazaki, M. Matsuda, A. Mari, and R. A. DeFronzo Thiazolidinediones improve beta-cell function in type 2 diabetic patients Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E871 - E883. [Abstract] [Full Text] [PDF]

				M. Hanefeld, N. Marx, A. Pfutzner, W. Baurecht, G. Lubben, E. Karagiannis, U. Stier, and T. Forst Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein: The PIOSTAT Study J. Am. Coll. Cardiol., January 23, 2007; 49(3): 290 - 297. [Abstract] [Full Text] [PDF]

				R. Bergeron, J. Yao, J. W. Woods, E. I. Zycband, C. Liu, Z. Li, A. Adams, J. P. Berger, B. B. Zhang, D. E. Moller, et al. Peroxisome Proliferator-Activated Receptor (PPAR)-{alpha} Agonism Prevents the Onset of Type 2 Diabetes in Zucker Diabetic Fatty Rats: A Comparison with PPAR{gamma} Agonism Endocrinology, September 1, 2006; 147(9): 4252 - 4262. [Abstract] [Full Text] [PDF]

				K. Esposito, M. Ciotola, D. Carleo, B. Schisano, F. Saccomanno, F. C. Sasso, D. Cozzolino, R. Assaloni, D. Merante, A. Ceriello, et al. Effect of Rosiglitazone on Endothelial Function and Inflammatory Markers in Patients With the Metabolic Syndrome Diabetes Care, May 1, 2006; 29(5): 1071 - 1076. [Abstract] [Full Text] [PDF]

				M. L. Christensen, B. Meibohm, E. V. Capparelli, P. Velasquez-Mieyer, G. A. Burghen, and W. V. Tamborlane Single- and Multiple-Dose Pharmacokinetics of Pioglitazone in Adolescents With Type 2 Diabetes J. Clin. Pharmacol., October 1, 2005; 45(10): 1137 - 1144. [Abstract] [Full Text] [PDF]

				M.R. Langenfeld, T. Forst, C. Hohberg, P. Kann, G. Lubben, T. Konrad, S.D. Fullert, C. Sachara, and A. Pfutzner Pioglitazone Decreases Carotid Intima-Media Thickness Independently of Glycemic Control in Patients With Type 2 Diabetes Mellitus: Results From a Controlled Randomized Study Circulation, May 17, 2005; 111(19): 2525 - 2531. [Abstract] [Full Text] [PDF]

				B. Kimmel and S. E. Inzucchi Oral Agents for Type 2 Diabetes: An Update Clin. Diabetes, April 1, 2005; 23(2): 64 - 76. [Abstract] [Full Text] [PDF]

				F. Kawasaki, M. Matsuda, Y. Kanda, H. Inoue, and K. Kaku Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice Am J Physiol Endocrinol Metab, March 1, 2005; 288(3): E510 - E518. [Abstract] [Full Text] [PDF]

				M. Abdelrahman, A. Sivarajah, and C. Thiemermann Beneficial effects of PPAR-{gamma} ligands in ischemia-reperfusion injury, inflammation and shock Cardiovasc Res, March 1, 2005; 65(4): 772 - 781. [Abstract] [Full Text] [PDF]

				A. Ceriello, D. Johns, M. Widel, D. J. Eckland, K. J. Gilmore, and M. H. Tan Comparison of Effect of Pioglitazone With Metformin or Sulfonylurea (Monotherapy and Combination Therapy) on Postload Glycemia and Composite Insulin Sensitivity Index During an Oral Glucose Tolerance Test in Patients With Type 2 Diabetes Diabetes Care, February 1, 2005; 28(2): 266 - 272. [Abstract] [Full Text] [PDF]

				D. Schuster, T. Gaillard, S. Rhinesmith, D. Habash, and K. Osei Impact of Metformin on Glucose Metabolism in Nondiabetic, Obese African Americans: A placebo-controlled, 24-month randomized study Diabetes Care, November 1, 2004; 27(11): 2768 - 2769. [Full Text] [PDF]

				E. Zeender, K. Maedler, D. Bosco, T. Berney, M. Y. Donath, and P. A. Halban Pioglitazone and Sodium Salicylate Protect Human {beta}-Cells against Apoptosis and Impaired Function Induced by Glucose and Interleukin-1{beta} J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5059 - 5066. [Abstract] [Full Text] [PDF]

				H. Yki-Jarvinen Thiazolidinediones N. Engl. J. Med., September 9, 2004; 351(11): 1106 - 1118. [Full Text] [PDF]

				Y. Miyazaki, A. Mahankali, E. Wajcberg, M. Bajaj, L. J. Mandarino, and R. A. DeFronzo Effect of Pioglitazone on Circulating Adipocytokine Levels and Insulin Sensitivity in Type 2 Diabetic Patients J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4312 - 4319. [Abstract] [Full Text] [PDF]

				A. M. Sironi, A. Gastaldelli, A. Mari, D. Ciociaro, V. Postano, E. Buzzigoli, S. Ghione, S. Turchi, M. Lombardi, and E. Ferrannini Visceral Fat in Hypertension: Influence on Insulin Resistance and {beta}-Cell Function Hypertension, August 1, 2004; 44(2): 127 - 133. [Abstract] [Full Text] [PDF]

				B. Charbonnel, J. Dormandy, E. Erdmann, M. Massi-Benedetti, and A. Skene The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive): Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5,238 patients Diabetes Care, July 1, 2004; 27(7): 1647 - 1653. [Abstract] [Full Text] [PDF]

				C. W. Yeckel, R. Weiss, J. Dziura, S. E. Taksali, S. Dufour, T. S. Burgert, W. V. Tamborlane, and S. Caprio Validation of Insulin Sensitivity Indices from Oral Glucose Tolerance Test Parameters in Obese Children and Adolescents J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1096 - 1101. [Abstract] [Full Text] [PDF]

				H. Bays, L. Mandarino, and R. A. DeFronzo Role of the Adipocyte, Free Fatty Acids, and Ectopic Fat in Pathogenesis of Type 2 Diabetes Mellitus: Peroxisomal Proliferator-Activated Receptor Agonists Provide a Rational Therapeutic Approach J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 463 - 478. [Full Text] [PDF]

				M. Hanefeld, P. Brunetti, G. H. Schernthaner, D. R. Matthews, and B. H. Charbonnel One-Year Glycemic Control With a Sulfonylurea Plus Pioglitazone Versus a Sulfonylurea Plus Metformin in Patients With Type 2 Diabetes Diabetes Care, January 1, 2004; 27(1): 141 - 147. [Abstract] [Full Text] [PDF]

				J. P.H. van Wijk, E. J.P. de Koning, E. P. Martens, and T. J. Rabelink Thiazolidinediones and Blood Lipids in Type 2 Diabetes Arterioscler. Thromb. Vasc. Biol., October 1, 2003; 23(10): 1744 - 1749. [Abstract] [Full Text] [PDF]

				W. N. Kernan, S. E. Inzucchi, C. M. Viscoli, L. M. Brass, D. M. Bravata, G. I. Shulman, J. C. McVeety, and R. I. Horwitz Pioglitazone Improves Insulin Sensitivity Among Nondiabetic Patients With a Recent Transient Ischemic Attack or Ischemic Stroke Stroke, June 1, 2003; 34(6): 1431 - 1436. [Abstract] [Full Text] [PDF]

I. Pavo, G. Jermendy, T. T. Varkonyi, Z. Kerenyi, A. Gyimesi, S. Shoustov, M. Shestakova, M. Herz, D. Johns, B. J. Schluchter, et al. Effect of Pioglitazone Compared with Metformin on Glycemic Control and Indicators of Insulin Sensitivity in Recently Diagnosed Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., April 1, 2